Health insurers and Medicare Part D prescription drug plans divide every covered medication into formulary tiers, a ranking system that determines your copay or coinsurance at the pharmacy counter. Most 2026 formularies use four to six tiers: Tier 1 for preferred generics, Tier 2 for non-preferred generics or preferred brand-name drugs, Tier 3 for non-preferred brand-name drugs, Tier 4 for higher-cost non-preferred drugs, and a specialty tier for the most expensive biologics and rare-disease treatments. The tier assigned to your prescription, not just whether it is a brand or generic, is the single biggest factor in what you pay each month. A drug moved from Tier 2 to Tier 3 during an annual formulary update can double or triple a patient's copay without any change to the prescription itself.
CMS sets the overall Part D benefit structure that formulary tiers operate inside. In 2026, the standard Part D deductible is $615, and the annual out-of-pocket cap is $2,100, the point at which covered drugs cost $0 for the remainder of the calendar year under Inflation Reduction Act rules. Within that structure, plans set their own tier count and cost-sharing amounts, subject to CMS review. Preferred brand-name drugs on Tier 3 typically carry coinsurance of 25% to 34% depending on plan type, according to KFF's 2026 Part D enrollment analysis. The specialty tier applies to any drug that costs more than $950 per month in 2026, per the CMS specialty-tier cost threshold, and specialty-tier coinsurance averages 25% to 28%.
Ten drugs entered Medicare's Maximum Fair Price program on January 1, 2026 under the Inflation Reduction Act of 2022, including Eliquis, Jardiance, and Enbrel. When a drug's negotiated Maximum Fair Price is lower than its prior list price, Part D plans generally pass that reduction through regardless of formulary tier placement, though the tier itself still determines whether prior authorization or step therapy applies before the plan approves the prescription. Medicaid, by contrast, uses a single preferred drug list rather than tiers, and copays are capped at $1 to $4 per prescription in most states in 2026. Patients moving between Medicare Part D and Medicaid, or applying for a low-income subsidy, should confirm which cost-sharing rules apply to their specific drug and plan.
What Formulary Tiers Explained Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same formulary tiers explained can cost many times more at a hospital than at your local pharmacy:
2026 Formulary Tiers Explained Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Tier 1: Preferred generic | $0 - $10 (30-day supply, 2026) | Lowest cost-sharing tier; nearly all common generics (atorvastatin, lisinopril, metformin) land here. |
| Tier 2: Non-preferred generic / preferred brand | $10 - $45 (30-day supply, 2026) | Some plans use a flat copay; others charge 15%-20% coinsurance instead. |
| Tier 3: Non-preferred brand | $40 - $100 or 25% - 34% coinsurance (2026) | Prior authorization or step therapy is often required before the plan approves the fill. |
| Tier 4: Non-preferred / high-cost drug | $90 - $150 or up to 40% coinsurance (2026) | Some plans merge Tier 4 into the specialty tier instead of keeping it separate. |
| Specialty tier | 25% - 33% coinsurance on drugs over $950/month (2026) | CMS-defined cost threshold; generally excluded from tiering exceptions to a lower tier since 2022. |
Copay and coinsurance amounts vary by specific plan and state. The 2026 Part D annual out-of-pocket cap is $2,100 per the Inflation Reduction Act; costs drop to $0 for covered drugs once that cap is reached.
Source: CMS Medicare Part D 2026 benefit parameters; KFF Medicare Part D 2026 enrollment and cost-sharing analysis
Why Hospitals Charge So Much
Pharmacy benefit managers, primarily CVS Caremark, Express Scripts, and OptumRx, design most commercial and Part D formularies and negotiate rebates directly with drug manufacturers. Placement on a low tier is often the result of a rebate deal between the manufacturer and the PBM, not necessarily the clinical value of the drug. A brand-name drug with a large rebate can sometimes land on Tier 2 while a cheaper competitor sits on Tier 3, because the PBM's formulary committee weighs net cost after rebates, not list price.
Specialty-tier drugs concentrate cost because they are biologics, gene therapies, or treatments for rare diseases that have no generic or biosimilar competition. Manufacturers set list prices with little competitive pressure, and CMS's 2026 specialty-tier threshold of $950 per month captures roughly 1,000 to 1,200 drugs nationally. When a specialty drug is administered by infusion in a clinic or hospital rather than picked up at a retail pharmacy, it may instead bill under the Medicare Part B medical benefit at facility rates, which can run far higher than the same drug's Part D specialty-tier coinsurance. Patients who receive a surprising hospital bill for an infused specialty drug can use the CoveredUSA Medical Bill Analyzer to check the charge against the Medicare ASP benchmark rate.
Formulary tier placement changes at least once a year, typically each January, and sometimes mid-year when a new generic or biosimilar launches. A plan may move a brand-name drug from Tier 2 to Tier 3, or add a new generic to Tier 1, without notifying every enrollee individually. Reviewing your plan's formulary each fall during Medicare's Annual Enrollment Period, or checking your commercial plan's updated drug list each January, is the only reliable way to catch a tier change before it hits your pharmacy bill.
Patient Assistance Programs
When a prescribed drug lands on Tier 3, Tier 4, or the specialty tier and the coinsurance is still unaffordable, several assistance routes exist outside the formulary system itself. These options work whether or not a formulary exception is approved:
Patient assistance programs for Formulary Tiers Explained| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NeedyMeds Patient Assistance Program Database | Directory of manufacturer patient assistance programs offering free or reduced-cost brand drugs; income typically ≤ 400% FPL | needymeds.org |
| GoodRx (pharmacy discount coupon) | Up to 80% off retail cash price; sometimes cheaper than a Tier 3 copay; free, no enrollment | goodrx.com |
| Mark Cuban Cost Plus Drugs | Generic drugs near wholesale cost plus a $3 pharmacist fee; bypasses formulary tiers entirely | costplusdrugs.com |
| Medicare Part D Extra Help (Low-Income Subsidy) | Caps copays at $5.10 generic / $12.65 brand in 2026 regardless of formulary tier for qualifying income | ssa.gov/benefits/medicare/prescriptionhelp |
| Manufacturer Patient Assistance Program (brand-specific) | Free drug for income-qualified, typically uninsured patients; requires per-drug enrollment | Search '[drug name] patient assistance program' or visit needymeds.org |
Manufacturer coupons and copay cards cannot be used by Medicare, Medicaid, TRICARE, or VA beneficiaries under the federal anti-kickback statute (42 U.S.C. § 1320a-7b), regardless of formulary tier. Income-based manufacturer patient assistance programs, which give the drug away rather than offering a coupon, remain available to Medicare and Medicaid enrollees.
Source: NeedyMeds.org, GoodRx.com, CostPlusDrugs.com, SSA.gov
Medicare Part D
Medicare Part D enrollees pay formulary tier cost-sharing until they reach the plan's initial coverage limit, move through the coverage gap phase, and finally reach the $2,100 annual out-of-pocket cap set for 2026. Once that cap is reached, Part D covers 100% of costs for covered formulary drugs for the rest of the calendar year, a protection created by the Inflation Reduction Act of 2022. Tier placement matters most in the months before that cap is reached.
Extra Help, Medicare's Low-Income Subsidy program, overrides standard formulary tier cost-sharing for enrollees with income up to roughly 150% of the federal poverty level in 2026. Full-subsidy enrollees pay no more than $1.60 for a generic or $4.90 for a brand-name drug if their income is at or below 100% FPL, and no more than $5.10 generic / $12.65 brand-name if their income is between 100% and 150% FPL, regardless of which tier the plan assigned the drug. Extra Help also eliminates the $615 deductible. Applications go through the Social Security Administration at ssa.gov.
Ten drugs, including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog, carry a Medicare-negotiated Maximum Fair Price effective January 1, 2026 under the Inflation Reduction Act. Part D plans must offer these Maximum Fair Prices to enrollees regardless of the drug's formulary tier, which means a patient's out-of-pocket cost for these ten specific drugs is now capped closer to the negotiated price rather than the plan's normal tier coinsurance percentage.
Common Formulary Tiers Explained Billing Errors
Common mistakes patients make with formulary tiers that lead to overpaying at the pharmacy counter:
- Assuming a generic drug is automatically Tier 1. Some non-preferred generics sit on Tier 2 or even Tier 3 depending on the plan's rebate agreements.
- Paying full non-preferred brand coinsurance without asking the prescriber to request a formulary exception first, even when a lower-tier clinical alternative may not exist.
- Not verifying that a mid-year formulary update moved a long-term prescription to a higher tier before refilling automatically through mail order.
- Continuing to pay tier-based copays after reaching the 2026 Part D annual out-of-pocket cap of $2,100, when covered drugs should cost $0 for the rest of the year.
- Using a manufacturer coupon at the pharmacy while enrolled in Medicare Part D, which most pharmacy systems will reject or which violates the federal anti-kickback statute if it does process.
Frequently Asked Questions
What is a drug formulary tier, and how many tiers exist in 2026?
A formulary tier is the cost-sharing category a health plan assigns to each covered drug. Most 2026 Medicare Part D and commercial plans use four to six tiers: Tier 1 (preferred generics, $0-$10), Tier 2 (non-preferred generics or preferred brands, $10-$45), Tier 3 (non-preferred brands, $40-$100 or 25%-34% coinsurance), Tier 4 (higher-cost non-preferred drugs), and a specialty tier for drugs costing more than $950 a month in 2026. The tier, not the drug's brand or generic status alone, determines your copay or coinsurance at the pharmacy.
Are generic and biosimilar drugs always on Tier 1?
No. Most generics land on Tier 1, the lowest-cost tier, but some non-preferred generics are assigned to Tier 2 based on the plan's rebate agreements with the manufacturer. Biosimilars, the near-identical copies of biologic drugs, usually appear on Tier 2 or Tier 3 rather than the specialty tier, which still cuts coinsurance significantly compared with the original brand-name biologic. Always confirm the exact tier with your plan's formulary before assuming a generic or biosimilar is automatically Tier 1.
Can I use a manufacturer coupon or savings card for a specialty-tier drug if I have Medicare?
No. Federal anti-kickback law (42 U.S.C. § 1320a-7b) prohibits Medicare, Medicaid, TRICARE, and VA enrollees from using manufacturer copay cards or coupons on any formulary tier, including the specialty tier. Instead, apply for the drug's manufacturer patient assistance program, which gives the drug away to income-qualified patients rather than subsidizing a copay, or apply for Medicare Extra Help (Low-Income Subsidy) through the Social Security Administration.
What if my insurance denies coverage or places my drug on a high tier?
Ask your prescriber to request a formulary or tiering exception with a written medical necessity statement. Part D plans must decide within 72 hours (24 hours if expedited). If denied, you can file a redetermination appeal within 60 days, then escalate through up to five appeal levels. Specialty-tier drugs are generally excluded from tiering exceptions to a lower tier since 2022, so a manufacturer patient assistance program or a generic/biosimilar switch is usually the faster path for those drugs.
Does the Inflation Reduction Act change formulary tier costs in 2026?
Yes, for ten specific drugs. Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog carry a Medicare-negotiated Maximum Fair Price effective January 1, 2026 under the Inflation Reduction Act, and Part D plans must pass that price through regardless of the drug's assigned tier. For every other drug, the law's main 2026 impact is the $2,100 annual Part D out-of-pocket cap and the elimination of cost-sharing after that cap is reached.
What does a specialty-tier drug cost without insurance in 2026?
Specialty-tier drugs, defined by CMS as costing more than $950 a month in 2026, often list for $2,000 to $20,000 or more per month in cash price without any coverage, since most are biologics or rare-disease treatments with no generic competition. With Part D coverage, specialty-tier coinsurance averages 25% to 28% until the $2,100 annual out-of-pocket cap is reached, after which the drug costs $0 for the rest of the year.
How do I apply for a tiering exception or a patient assistance program?
Start by asking your prescriber to submit a coverage determination request with a medical necessity statement to your Part D plan; a decision is required within 72 hours. If that is denied or your drug is on the specialty tier, apply directly to the manufacturer's patient assistance program (search '[drug name] patient assistance program' or visit needymeds.org) with proof of income, proof of insurance status, and your prescription. Most PAPs use an income cutoff around 400% of the federal poverty level.
What's the difference between a copay and coinsurance on a formulary tier?
A copay is a fixed dollar amount, such as $10 for a Tier 1 generic, regardless of the drug's actual cost. Coinsurance is a percentage of the drug's negotiated price, such as 25% for a Tier 3 non-preferred brand, so the dollar amount changes with the drug's price. Lower tiers (1 and 2) typically use flat copays, while higher tiers (3, 4, and specialty) increasingly use coinsurance in 2026, which is why costs on those tiers vary more between plans.
